Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975236 | 0.69 | CYP1B1 (0.39) | — | |
| SCHEMBL5402128 | 0.68 | MPO (0.43) | MPOPDE10AACHEHRH4FBP1 | |
| SCHEMBL7427955 | 0.68 | MPO (0.46) | MPOPDE10AACHEHRH4FBP1 | |
| SCHEMBL3974657 | 0.67 | SLC2A1 (0.50) | FBP1 | |
| SCHEMBL5397567 | 0.66 | PTGES (0.42) | MPOPDE10AACHEHRH4FBP1 | |
| SCHEMBL6923005 | 0.65 | PARP1 (0.48) | PDE10ACHEK1 | |
| SCHEMBL5401620 | 0.65 | ACP1 (0.46) | TLR8FBP1 | |
| SCHEMBL11985926 | 0.64 | MPO (0.49) | MPOACHEHRH4F2NQO2 | |
| SCHEMBL5225815 | 0.64 | PYCR1 (0.41) | MPOCHEK1HRH1 | |
| SCHEMBL3974636 | 0.63 | ADORA3 (0.47) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1318981-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
| WO-2002020488-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176698-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | MPO 2731/4885TLR8 1718/4885PDE10A 1484/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | MPO 2731/4885TLR8 1718/4885PDE10A 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.